Nanobiotix Stock Quote NBTX - Stock Price, News, Charts, Message Board, Trades

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Nanobiotix SA (NBTX) Quote

Nanobiotix SA (NBTX)

5.81

0.07

( 1.22% )

Updated: 11:30:00

Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Current Price

5.81

Bid

5.70

Ask

5.90

Volume

1,555

5.701 Day's Range 5.81

0.00 52 Week Range 0.00

Market Cap

Previous Close

5.74

Open

5.71

Last Trade

Last Trade Time

11:45:34

Financial Volume

$ 8,961

VWAP

5.7626

Average Volume (3m)

-

Shares Outstanding

34,876,000

Dividend Yield

-

PE Ratio

-3.35

Earnings Per Share (EPS)

-1.64

Revenue

4.78M

Net Profit

-57.04M

Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying ... Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its lead product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.nanobiotix.com

Headquarters

Paris, Paris, Fra

Founded

1970

Nanobiotix SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NBTX. The last closing price for Nanobiotix was $5.74. Over the last year, Nanobiotix shares have traded in a share price range of $ 0.00 to $ 0.00.

Nanobiotix currently has 34,876,000 shares outstanding. The market capitalization of Nanobiotix is $191.12 million. Nanobiotix has a price to earnings ratio (PE ratio) of -3.35.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CAUDCollective Audience Inc	$ 0.7912 (102.87%)	130.75M
DCPHDeciphera Pharmaceuticals Inc	$ 25.21 (72.08%)	38.48M
SINTSiNtx Technologies Inc	$ 0.0559 (38.37%)	127.46M
HWHHWH International Inc	$ 2.5102 (37.92%)	21.87M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 9.5912 (34.14%)	57.02M
CLVRClever Leaves Holdings Inc	$ 1.61 (-60.83%)	593.93k
ADXNAddex Therapeutics Ltd	$ 8.50 (-47.20%)	115.44k
TSDDGraniteShares ETF Trust GraniteShares	$ 16.4565 (-33.91%)	987.18k
TSLZT Rex 2X Inverse Tesla Daily Target ETF	$ 25.9955 (-33.80%)	5.04M
MFImF International Ltd	$ 1.64 (-29.61%)	2.29M
TSLATesla Inc	$ 196.915 (17.01%)	143.16M
CAUDCollective Audience Inc	$ 0.7912 (102.87%)	130.76M
SINTSiNtx Technologies Inc	$ 0.0559 (38.37%)	127.46M
SOFISoFi Technologies Inc	$ 7.0982 (-9.81%)	108.54M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 9.5912 (34.14%)	57.02M

Monksdream

Monksdream 4 weeks ago

NBTX 10Q due 4/3

Monksdream

Monksdream 4 weeks ago

Monksdream

Monksdream 9 months ago

Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees

Monksdream

Monksdream 10 months ago

July 10, 2023
4:21 am ET
*Nanobiotix shares are trading higher after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
Benzinga
2:19 am ET
*Nanobiotix Enters License Agreement With Janssen Pharmaceutical For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Benzinga
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions